Pfizer shares hover near the 52‑week high but the valuation now aligns with sector fair‑value ranges, limiting upside potential. The technical chart shows a flat to slightly descending trend as price tests resistance.

Investor enthusiasm stays strong after the recent earnings beat and FDA vaccine approval, sustaining buying pressure. Momentum from the rally keeps the sentiment bullish.

The pipeline remains robust, yet the stock trades at a premium that leaves little cushion for adverse news. Any regulatory or trial setback could quickly erode value.

Price remains above the 20‑day EMA with a rising MACD and RSI around 58, indicating healthy momentum without being overbought. Volume spikes on recent up days support continued bullish bias.